Publications by authors named "K A Clarke"

Background: Understanding the risk of hospitalization from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can guide effective public health interventions and severity assessments. This study calculated infection-hospitalization ratios (IHRs) and infection-case ratios (ICRs) to understand the relationship between SARS-CoV-2 infections, cases, and hospitalizations among different age groups during periods of Delta and Omicron variant predominance.

Methods: After calculating antinucleocapsid SARS-CoV-2 antibody seroprevalence using residual commercial laboratory serum specimens, 2 ratios were computed: (1) IHRs using coronavirus disease 2019 hospitalization data and (2) ICRs using Centers for Disease Control and Prevention surveillance data.

View Article and Find Full Text PDF

Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.

Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.

View Article and Find Full Text PDF

Objectives: To assess the incidence and clinical findings associated with the presence of ammonium urate urolithiasis in dogs with congenital portosystemic shunts.

Materials And Methods: A retrospective review of dogs diagnosed with extrahepatic portosystemic shunts or intrahepatic portosystemic shunts in 15 referral hospitals between 2010 and 2023. Data including signalment, clinical signs, physical examination findings and clinicopathologic test results at the time of the diagnosis were collected, and the presence of ammonium urate urolithiasis was recorded.

View Article and Find Full Text PDF

Objective: Pediatric cardiac surgery site infections (SSI) represent significant morbidity. Our institution reported elevated SSI rates of 3.48 per 100 cases over a 5-year period above target rates of 2.

View Article and Find Full Text PDF

People with immunocompromising conditions (IC) are at increased risk of severe COVID-19 and death. These individuals show weaker immunogenicity following vaccination than individuals without IC, yet immunogenicity after SARS-CoV-2 infection is poorly understood. To address this gap, the presence of infection-induced antibodies in sera following a positive COVID-19 test result was compared between patients with and without IC.

View Article and Find Full Text PDF